scholarly journals THE MANAGEMENT OF AMAVATA (RHEUMATOID ARTHRITIS) WITH VATARI GUGGULU AND BRIHAT SIMHANADA GUGGULU

2021 ◽  
Vol 9 (2) ◽  
pp. 335-342
Author(s):  
Praveen Kumar ◽  
Sriram Chandra Mishra ◽  
Vandana Gupta
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Research ◽  
Therapeutic Approach ◽  
Severe Pain ◽  
Clinical Entity ◽  
Moderate Improvement ◽  
Mild Improvement ◽  
Pathogenic Factors ◽  
Inflammatory Arthropathy ◽  
Principles Of Treatment

The detail knowledge on Amavata was first explained by Madhavakar, whereas Chakrapani Dutta first gave knowledge about principle and management of the disease. Amavata is a clinical entity very much similar to the chronic but active inflammatory arthropathy, the Rheumatoid arthritis. Till now, the etio-pathogenesis of Rheumatoid arthritis is not known precisely but among the hypothesis, entero-pathy along with autoimmune have important role regarding this disease. In Amavata, due to impaired functioning of 'Kayagni' the anna-rasa undergoes fermentation resulted formation of ama (biotoxin) which combines with vitiated Vata (biophysical force for movement) to form Amavata.(1) So, two important entities one is toxin and other is movement, when comes together kha vaigunya concept the disease formed which is worst one. That’s why swelling, severe pain, and restricted movements are the main features of Amavata. Severe pain, difficulty in movements, and swelling on the joints along with fever etc makes the patient’s life miserable. Although Ama and Vata are chiefly pathogenic factors, Kapha and Pitta are also invariably involved in its pathogenesis (Samprapti). The therapeutic approach should be on Vata dosha, Kapha dosha and correction of Amadosha and of Agni viz. Pitta. The line of treatment for amavata also includes langhanam, swedanam, tiktam, deepana, katu drugs and sodhana treatment like virechana, basti etc. The shamana drugs which are having Vatashamaka, Amapachaka, Ama Shoshaka, and Deepniya properties can be used in the treatment of this disease. Vatari Guggulu and Brihat simhanada guggulu carries indication for Amavata according to Bhaisajya Ratnavali. The compositions in it are approachable lieu of principles of treatment of Amavata. The clinical research shows that in TG I, 7 (46.67%) patients were got Moderate im-provement while 8 (53.33%) patients were got Mild improvement. In TG II 10 (66.67%) patients were get Moderate improvement while 5 (33.33%) patients were got Mild improvement.

scholarly journals SAT0006 SIMULTANEOUS ANALYSIS OF ANTI-CCP, RHEUMATOID FACTOR, ANTI-PAD4 AND ANTI-CARBAMYLATED PROTEIN ANTIBODIES REVEALS INTERACTION EFFECTS WITH RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 933.2-934
Author(s):  
A. Julià ◽  
M. Lopez Lasanta ◽  
F. Blanco ◽  
A. Gómez ◽  
I. Haro ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Factor ◽  
Clinical Response ◽  
Therapeutic Approach ◽  
Drug Response ◽  
Single Marker Analysis ◽  
Das28 Score ◽  
Positive Interaction ◽  
Single Marker ◽  
Necrosis Factor

Background:Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 2 out of 3 Rheumatoid Arthritis patients. Identifying the patients that will not respond to this therapeutic approach is a major translational goal in RA. Association of seropositivity to rheumatoid factor (RF) or anti-cyclic-citrullinated antibodies (anti-CCP) with anti-TNF response has proven inconclusive, suggesting that other yet unexplored biomarkers could be more informative for this goal.Objectives:We tested the association of two recently introduced biomarkers in RA: anti-carbamylated protein antibodies (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4).Methods:A prospective cohort of n=80 RA patients starting anti-TNF therapy was recruited and levels for all four autoantibodies -RF, anti-CCP, anti-CarP and anti-PAD4- were measured at baseline. The change in DAS28 score between baseline and week 12 of therapy was used as the clinical endpoint.Results:Single marker-analysis showed no significant association with drug response. However, when testing for interactions between autoantibodies, we found highly significant associations with drug response. Anti-CCP and RF showed a positive interaction with the response to anti-TNF therapy (P=0.00068), and anti-PAD4 and antiCarP titers showed a negative interaction with the clinical response at week 12 (P=0.0062). Using an independent retrospective sample (n=199 patients), we validated the interaction between anti-CCP and RF with the clinical response to anti-TNF agents. (P=0.044).Conclusion:The results of this study show that interactions between antibodies are important in the response to anti-TNF therapy and suggest potential pathogenic relationships.Acknowledgments :We would like to thank the clinical researchers and patients participating in the IMID Consortium for their collaborationDisclosure of Interests:Antonio Julià: None declared, Maria Lopez Lasanta: None declared, Francisco Blanco: None declared, Antonio Gómez: None declared, Isabel Haro: None declared, Antonio Juan Mas: None declared, Alba Erra: None declared, Mª Luz García Vivar: None declared, Jordi Monfort: None declared, Simon Sánchez Fernandez: None declared, Isidoro González-Álvaro Grant/research support from: Roche Laboratories, Consultant of: Lilly, Sanofi, Paid instructor for: Lilly, Speakers bureau: Abbvie, MSD, Roche, Lilly, Mercedes Alperi-López: None declared, Raúl Castellanos: None declared, Antonio Fernandez-Nebro: None declared, Cesar Diaz Torne: None declared, Núria Palau: None declared, Raquel M Lastra: None declared, Jordi Lladós: None declared, Raimon Sanmarti: None declared, Sara Marsal: None declared

SAT0196 Dekavil (F8-IL10), A Novel Therapeutic Approach for Rheumatoid Arthritis: Ongoing Phase IB Clinical Trial Results

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 726.2-727 ◽  
Author(s):  
M. Galeazzi ◽  
G.D. Sebastiani ◽  
L. Bazzichi ◽  
E. Garcia Gonzalez ◽  
N. Ravenni ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Therapeutic Approach ◽  
Phase Ib ◽  
Clinical Trial Results ◽  
Ongoing Phase ◽  
Novel Therapeutic

scholarly journals A COMPARATIVE CLINICAL STUDY ON THE EFFECT OF ASHTAVARGAM KASHAYA AND GANDHARVAHASTHADI KASHAYA IN THE MANAGEMENT OF KATIGRAHA w.s.r. TO LUMBAR SPONDYLOSIS

2020 ◽  
Vol 8 (8) ◽  
pp. 4036-4042
Author(s):  
Abeena Raj D P ◽  
Shripathi Acharya
Keyword(s):  
Clinical Study ◽  
Food Habits ◽  
Unhealthy Food ◽  
Lumbar Spondylosis ◽  
Moderate Improvement ◽  
Nutritional Deficit ◽  
Mild Improvement ◽  
Comparative Clinical Study ◽  
Group A ◽  
Group B

Katigraha is a condition in which the vitiated Vata is localizing in the Katipradesha and producing stiff-ness and pain. These symptoms are similar to Lumbar Spondylosis. The degenerative changes due to aging or trauma, changing in lifestyle & work pattern, unhealthy food habits causing nutritional deficit etc., are causing Dhatukshaya and Margavarodha. Here Ashtavarga & Gandharvahasthadi Kashayas are taken to evaluate the effect on Katigraha. Totally 40 patients of Katigraha were selected, divided in to two groups equally. Group A treated with Ashtavargamkashaya and Group B treated with Gandharvahasthadi Kashaya for 30 days. In group A, 55% patients got moderate improvement and 40% patients with mild im-provement in group B, 5%got moderate improvement and 60% got mild improvement. It is concluded that in general statistically significant results were seen in both the groups. AshtavargamKashaya showed better efficacy than Gandharvahasthadikashaya.

scholarly journals Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice

2000 ◽  
Vol 191 (2) ◽  
pp. 313-320 ◽  
Author(s):  
Reiko Horai ◽  
Shinobu Saijo ◽  
Hidetoshi Tanioka ◽  
Susumu Nakae ◽  
Katsuko Sudo ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Receptor Antagonist ◽  
Interleukin 1 ◽  
Type Ii Collagen ◽  
Cytokine Network ◽  
Gene Deficiency ◽  
Double Stranded Dna ◽  
Inflammatory Arthropathy ◽  
Factor Α ◽  
Deficient Mice

Interleukin (IL)-1 is a proinflammatory cytokine that plays important roles in inflammation, host defense, and the neuro-immuno-endocrine network. IL-1 receptor antagonist (ra) is an endogenous inhibitor of IL-1 and is supposed to regulate IL-1 activity. However, its pathophysiological roles in a body remain largely unknown. To elucidate the roles of IL-1ra, IL-1ra–deficient mice were produced by gene targeting, and pathology was analyzed on different genetic backgrounds. We found that all of the mice on a BALB/cA background, but not those on a C57BL/6J background, spontaneously developed chronic inflammatory polyarthropathy. Histopathology showed marked synovial and periarticular inflammation, with articular erosion caused by invasion of granulation tissues closely resembling that of rheumatoid arthritis in humans. Moreover, elevated levels of antibodies against immunoglobulins, type II collagen, and double-stranded DNA were detected in these mice, suggesting development of autoimmunity. Proinflammatory cytokines such as IL-1β, IL-6, and tumor necrosis factor α were overexpressed in the joints, indicating regulatory roles of IL-1ra in the cytokine network. We thus show that IL-1ra gene deficiency causes autoimmunity and joint-specific inflammation and suggest that IL-1ra is important in maintaining homeostasis of the immune system. Possible involvement of IL-1ra gene deficiency in RA will be discussed.

Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I

Science ◽  
1991 ◽  
Vol 253 (5023) ◽  
pp. 1026-1028 ◽  
Author(s):  
Y. Iwakura ◽  
M. Tosu ◽  
E. Yoshida ◽  
M. Takiguchi ◽  
K. Sato ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Inflammatory Arthropathy

scholarly journals Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-4 ◽  
Author(s):  
Caterina Vacchi ◽  
Andreina Manfredi ◽  
Giulia Cassone ◽  
Carlo Salvarani ◽  
Stefania Cerri ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interstitial Lung Disease ◽  
Combination Therapy ◽  
Lung Disease ◽  
Therapeutic Approach ◽  
Negative Impact ◽  
Case Series ◽  
Joint Involvement ◽  
Sustained Remission ◽  
Systemic Inflammatory Disease

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease characterized by joint and extra-articular involvement. Among them, interstitial lung disease (ILD) is one of the most common and severe extra-articular manifestations, with a negative impact on both therapeutic approach and overall prognosis. ILD can occur at any point of the natural history of RA, sometimes before the appearance of joint involvement. Since no controlled studies are available, the therapeutic approach to RA-ILD is still debated and based on empirical approaches dependent on retrospective studies and case series. Here, we report the case of a 75-year-old patient affected by RA complicated by ILD successfully treated with a combination therapy of an antifibrotic agent, nintedanib, and an inhibitor of IL-6 receptor, sarilumab. We obtained a sustained remission of the joint involvement and, simultaneously, a stabilization of the respiratory symptoms and function, with a good safety profile. To date, this is the first report describing a combination therapy with nintedanib and a disease-modifying antirheumatic drug (DMARD) for the management of RA complicated by ILD. Future prospective studies are needed to better define efficacy and safety of this approach in the treatment of these subjects.

scholarly journals Amantadine Therapy for Fatigue in Multiple Sclerosis

1985 ◽  
Vol 12 (3) ◽  
pp. 251-254 ◽  
Author(s):  
T.J. Murray
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Marked Improvement ◽  
Double Blind ◽  
Moderate Improvement ◽  
Mild Improvement ◽  
Double Blind Control Study ◽  
Control Study

ABSTRACT:We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo. On amantadine 31% had marked improvement; 15.6% moderate improvement; 15.6% mild improvement; and 36.5%unchanged. On placebo, none noted marked improvement; one claimed moderate improvement on either amantadine or placebo. 18.7% reported mild improvement on placebo; and most of them had similar or more response to amantadine. No patient selected placebo over amantadine at the end of the trial. Overall improvement was seen in 62.5% of patients on amantadine and 21.8% on placebo. Additional experience up to two years suggests continued benefit but common and important side-effects.

The evolution of biomarkers in rheumatoid arthritis: From clinical research to clinical care

2008 ◽  
Vol 8 (11) ◽  
pp. 1773-1785 ◽  
Author(s):  
Theodorus van den Broek ◽  
John RP Tesser ◽  
Salvatore Albani
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Research ◽  
Clinical Care
Sign in / Sign up

Export Citation Format

Share Document